Sudarshan Pharma to buy 9.5% of US cancer-therapy firm MedTherapy
What's the deal? Sudarshan Pharma IndustriesDealroom has a profile for this one. Try Dealroom → has approved buying a 9.5% stake — 2,423,675 shares — in MedTherapy BiotechnologyDealroom has a profile for this one. Try Dealroom →, a Boston-based oncology cell and gene therapy firm. The cash consideration was not disclosed. Chairman and managing director Hemal Mehta and joint managing director Sachin Mehta will each take a separate 1.5% stake.
What's the endgame? The deal gives Sudarshan Pharma its entry into the US market and into CAR-T cell and gene therapy. MedTherapy operates as a contract development and manufacturing organisation, with operations in Boston and a GMP facility in New Delhi.
Why now? Sudarshan aims to tap MedTherapy's existing distribution networks and customer contracts to build a US footing, while adding advanced cancer-treatment capabilities to its portfolio.
What changes now? The transaction moves into due diligence and regulatory review. Because it is an overseas investment, the company must secure clearance from the Reserve Bank of India under Foreign Exchange Management Act guidelines. Completion is targeted for March 31, 2027.
What could go wrong? The deal is conditional on timely regulatory approval and on integrating international operations. With the consideration undisclosed, the impact on Sudarshan's balance sheet cannot yet be assessed.
The signal: A mid-tier Indian pharma company is buying into US-based advanced-therapy manufacturing rather than building it, using a minority stake to access oncology's fastest-growing treatment segment.
Read more: whalesbook.com
Image credit: Generated with Gemini
